Ignite Creation Date:
2025-12-24 @ 12:06 PM
Ignite Modification Date:
2026-02-10 @ 10:31 AM
Study NCT ID:
NCT03030261
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-12-18
First Post:
2017-01-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Sponsor:
Washington University School of Medicine
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-11-22
Start Date Type:
ACTUAL
Primary Completion Date:
2022-09-29
Primary Completion Date Type:
ACTUAL
Completion Date:
2027-09-26
Completion Date Type:
ESTIMATED
First Submit Date:
2017-01-18
First Submit QC Date:
None
Study First Post Date:
2017-01-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-09-20
Results First Submit QC Date:
None
Results First Post Date:
2023-12-15
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-12-16
Last Update Post Date:
2024-12-18
Last Update Post Date Type:
ACTUAL